

Pataula Charter Academy

Spring Creek Charter Academy

TITLE: Self Administration of Prescription Asthma or Epinephrine Medication Policy

APPROVED BY: The Governing Board

REFERENCES: O.C.G.A 20-02-0774 & 20-02-0776 (see attached)

PURPOSE:

The purpose of this policy is to provide Pataula Charter Academy and Spring Creek Charter Academy with the guidelines for the safe and appropriate use of self-administered prescription asthma and auto-injectable epinephrine medications by students, as well as to ensure the compliance with O.C.G.A 20-02-0774 and 20-02-0776.

DEFINITIONS:

Asthma-a chronic lung disease with recurring symptoms, including wheezing, breathlessness, chest tightness, and coughing.

Self Administration of asthma Medication- a student's discretionary use of asthma medication prescribed for him or her.

Auto-injectable epinephrine- a disposable drug delivery device that is easily transportable and contains a pre-measured single dose of epinephrine used to treat life-threatening allergic reactions.

Medication-as used in this policy means a medication prescribed by:

1. A physician licensed under Chapter 34 of Title 43; or
2. A physician assistant licensed under Chapter 34 of Title 43 who is authorized to prescribe medicine for the treatment of asthma in accordance with said chapter.
3. A certified registered nurse practitioner licensed under O.C.G.A 43-34-25 with a nurse protocol agreement with prescriptive authority who is authorized to prescribe medication for the treatment of asthma in accordance with said law and protocol agreement.

POLICY:

Pataula Charter Academy and Spring Creek Charter Academy shall allow a student, who is identified as qualified, to possess and self administer prescription asthma medication or auto-injectable epinephrine while:

1. In school
2. At a school sponsored activity
3. While under the supervision of school personnel
4. While in before-school or after-school care on school operated property

Pataula Charter Academy and Spring Creek Charter Academy and their employees and agents shall incur no liability other than from willful or wanton misconduct for any injury to a student caused by his or her self-administration of asthma or auto-injectable epinephrine medication.

With regards to the authorization of a student to possess and self-administer prescription asthma or auto-injectable epinephrine medication, Pataula Charter Academy and Spring Creek Charter Academy shall require the parent or legal guardian (annually or more frequently if the prescription should changed) to:

1. Provide a written statement from the student's healthcare practitioner verifying:
 - a. that the student has a condition requiring the medication, and that the healthcare practitioner prescribed the medication.
 - b. the details of the medication including, but not limited to, the
 - Name
 - Method by which it is to be taken
 - Amount that is to be taken

- potential serious reactions and emergency response.
- c. that the student has been instructed in self-administration of the medication, and
 - d. that the student has demonstrated the skill level necessary to use the medication device to administer the medication.

2. Provide a written statement from themselves acknowledging:

- a. consent for the student to possess and self-administer the medication as ordered by the student's healthcare practitioner.
- b. Consent for the school to consult the physician regarding the medication and
- c. that the school and its employees and agents shall incur no liability other than from willful or wanton misconduct for any injury to a student caused by his or her self administration of the medication.

3. Provide a written statement from the student acknowledging:

- a. that he or she will use the medication only as prescribed, and
- b. that he or she may be subject to disciplinary action if the medication is used in a manner other than as prescribed, according to the disciplinary action policy, as long as the action does not limit or restrict the student's immediate access to the medication.

Reviewed/ Revised	Revised							
Date/ Initial	6/21 KRF							
Board Approved Date	7/26/2021							